A recent network meta-analysis by Chen et al indicated that SGLT-2 inhibitors significantly reduced cardiovascular mortality and heart failure incidents by 25% (risk ratio [RR]=0.75, respectively) in CKD patients.16 The gene discussed is SLC5A2; the disease is chronic kidney disease.